Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Paclitaxel vs Paclitaxel + Carboplatin in TNBC
NCT03168880Phase 3Active, not recruiting
- Sponsor
- Tata Memorial Hospital
- Start
- Apr 2010
- Primary completion
- Nov 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised trial of carboplatin in triple-negative breast cancer (TNBC) (2 arms), sponsored by Tata Memorial Hospital. Primary endpoints: Disease-Free Survival at 60 months and Overall Survival at 60 months. Started Apr 2010; status: active, not recruiting.
02
Drugs
carboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03168880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03168880.